Work

HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series

Year: 2025

Type: article

Abstract: Lenacapavir, a long-acting human immunodeficiency virus (HIV) capsid inhibitor, is thought to have a low resistance barrier based on current, limited data. We describe 4 patients experiencing homelessness with severe mental illness who maintained HIV suppression (<30 copies/mL) despite unintentional receipt of lenacapavir monotherapy for 9-38 weeks, highlighting its potential among adherence-challenged populations.

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofaf330

Authors: Nicky J Mehtani, Janet Grochowski, Anthonia Chimezie, Alix Strough, Sarah Strieff, Monica Gandhi

Institutions: University of California, San Francisco, San Francisco Department of Public Health

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,053